miophthalmology products
RetinaVue 100PRO Imager
Designed for busy clinicians and eye specialists who need great image quality and portability, the Welch Allyn RetinaVue 100PRO Imager offers access to diabetic eye exams with a simple, affordable, and flexible solution at the point of care. Can assist in early detection of diabetic retinopathy.
Aurora IQ Fundus Camera
The handheld Aurora IQ fundus camera has a sleek modern design with a new high contrast optical design that further enhances image quality to detect early phase retinal changes. Additional features include autofocus and autoexposure, integrated image quality analysis, and artificial intelligence (AI).
Its compact size with wireless or USB connectivity makes the Aurora IQ ideal for handheld or slit lamp mounted use.
Contact: BOC Instruments (AUS) 1800 804 331
iCare DRSplus
Setting the standard for image quality, the iCare DRSplus fundus imaging system offers optional artificial intelligence (AI) to screen for pathology like diabetic retinopathy.
The unique TrueColor confocal technology captures images of superior clarity and natural colour rendition, enabling the screening software to accurately assess a patient’s retinal status. Images are securely stored, and the report is available instantly. The screening process doesn’t require dilation, capturing through pupils as small as 2.5mm – even through moderate cataract and vitreous opacities.
Contact: Designs for Vision (AUS) 1800 225 307 or (NZ) 0800 338 800
IntegreTM Pro Scan
Ellex’s Integre Pro Scan transforms retinal photocoagulation by combining multi-colour photocoagulation with a precise computer-controlled pattern scanning laser in an ergonomically advanced all-in-one laser/slit lamp design. Whether positioning focal treatment in the macular area, or performing PRP in the periphery, Integre Pro Scan provides a comprehensive pattern and wavelength choice to cover all retinal pathologies.
Contact: salesadmin@ellex.com
CSO Cobra+
Cobra+ is a leading edge, user-centric, non-mydriatic digital fundus camera for early detection of glaucomatous and age-related macular diseases. It produces retinal images up to a 50 degree visual field and can capture images through small pupils with a diameter of 2.5mm.
In combination with CSO Phoenix software and the CSO Retimax, the retinal image can be overlapped with ERG multifocal testing. This combination provides comprehensive retinal profiles and the precise health indicators of every analysed retinal area.
Visit: www.eyetek.com.au
iCare Eidon
The iCare Eidon family offers the best of TrueColor confocal technology, delivering benefits of increased image sharpness, better optical resolution, and greater contrast over a 200° field. Early detection and monitoring of subtle signs of pathologies in the peripheral retina are made simple within the Eidon’s functionality including RGB, fundus autofluorescence, and fluorescein angiography.
Visit: www.icare-world.com
Opticare Visionix
Visionix VX650 is a single multi-modal instrument for complete detection and follow-up of major anterior and posterior ocular pathologies. It combines an aberrometer, a fundus camera, and all essential technologies to monitor both anterior and posterior segments in a single device. It detects all major defects and pathologies, including diabetic retinopathy, dry eye, keratoconus, cataract, glaucoma, nevus, retinal haemorrhage, and more.
Visit: www.opticare.com.au
Topcon Harmony Data
Management Solution
Topcon Harmony is a web-based data management platform connecting ophthalmic instruments, eye care professionals, and innovative technologies to help drive efficiency and accuracy in clinical workflows.
Visit: topconhealthcare.com.au
Vision Australia
Partner with Vision Store for better diabetic management.
Your blind or low vision patient will love Vision Australia's blood glucose monitor. It is equipped with a talking function, large screen, and large print logbook to enhance their independence.
Visit: shop.visionaustralia.org
Vision Australia
The Clarus 700 from Zeiss represents a comprehensive ultra-widefield retinal camera for eye care specialists to capture ultra-widefield images in true colour, with unsurpassed image quality and a complete suite of modalities. This includes fluorescein angiography, a particularly useful exam in the identification of diabetic retinopathy.
Contact: Zeiss Surgical Account Manager
Vabysmo
Vabysmo (faricimab) is the only bispecific antibody registered with the Australian Register of Therapeutic Goods for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).1,2
This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 Vabysmo is approved in 53 countries worldwide and has been studied extensively in over 1,900 patients with 23,000 injections given in Phase 3 clinical trials.1,3,4
Contact: Roche (AUS) 1800 233 950
Please review the Product Information before prescribing, available here: www.roche-australia.com/productinfo/vabysmo. VABYSMO▼ is listed on the PBS for nAMD and DMO. Refer to PBS Schedule for full authority information.
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at ww.tga.gov.au/reporting-problems.
Further information is available from Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney, NSW 2000. Medical Information: www.medinfo.roche.com/australia or 1800 233 950. Vabysmo is a Registered Trademark. M-AU-00002420. Prepared Mar 23.
References
1. Vabysmo Approved Product Information. Available at www.roche-australia.com/productinfo/vabysmo.
2. Australian Government Department of Health and Aged Care. Australian Register of Therapeutic Goods. Available at:.gov.au/resources/artg [accessed 27 January 2023].
3. Roche Internal Regulatory Document. [Accessed 1 February 2023].
4. Jaffe, G.J., et al., Overview of the Faricimab Safety Profile From Four Phase 3 Trials in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration Through 2 Years, presented at Retina Society 2022.